INS and metabolic disease: As a hypoglycemic drug, Gli induces insulin secretion, but is also reported to cause “secondary failure” of insulin secretion capacity in long-term usage on diabetic patients.46 Since both insulin resistance and failure of insulin secretion feature the age-related metabolic disorders, we tested the serum insulin level in aged mice.